Tranilast

Tranilast Market Outlook

The global Tranilast market is projected to reach approximately USD 1.2 billion by 2035, growing at a CAGR of about 6.4% during the forecast period from 2025 to 2035. This growth is attributed to the increasing prevalence of allergic diseases, skin disorders, and chronic inflammatory conditions where Tranilast is commonly prescribed. Moreover, the rise in the geriatric population, who are more susceptible to such health issues, has further intensified the market demand. The expanding awareness regarding the therapeutic effects of Tranilast in managing various diseases, coupled with advancements in healthcare infrastructure and increased healthcare spending, are also significant factors contributing to market growth. Additionally, the ongoing research and development initiatives aimed at exploring new applications of Tranilast are expected to open new avenues for market expansion.

Growth Factor of the Market

Several factors are propelling the growth of the Tranilast market. Firstly, the rising incidences of allergic conditions, particularly in urban areas, are creating a substantial demand for effective medical treatments, with Tranilast emerging as a preferred choice among healthcare professionals. Secondly, ongoing clinical research has been unveiling new therapeutic potentials of Tranilast in treating ailments beyond its traditional uses, including its efficacy in managing certain cancers and cardiovascular diseases, which is attracting attention from the medical community. Thirdly, improved healthcare access in developing regions is enabling more patients to receive necessary treatments, thus escalating the market's growth trajectory. Moreover, the rise of online pharmacies has made access to Tranilast easier for consumers, thereby increasing sales volumes. Lastly, government initiatives aimed at enhancing healthcare services and pharmaceutical supply chains are expected to foster a conducive environment for the further expansion of the Tranilast market.

Key Highlights of the Market

• The global Tranilast market is anticipated to witness significant growth driven by rising allergic conditions.
• Oral tablets are projected to dominate the product type segment due to their convenience and effectiveness.
• Dermatology applications are leading the market share, reflecting the drug's efficacy in skin disorders.
• Online pharmacies are growing rapidly as a preferred distribution channel owing to their accessibility.
• Asia Pacific is expected to exhibit the highest CAGR due to increasing healthcare access and rising awareness.

By Product Type

Oral Tablets:

Oral tablets represent the most significant product type in the Tranilast market, accounting for a substantial share due to their ease of administration and widespread acceptance among patients. These tablets are formulated to provide controlled-release of the active ingredient, ensuring effective management of allergic conditions and inflammation. The convenience of oral administration allows for better patient compliance, making it a preferred choice for both healthcare providers and patients. Additionally, ongoing advancements in pharmaceutical formulations have led to the development of oral tablets with enhanced bioavailability, further boosting their demand. The increasing number of prescriptions for oral Tranilast by healthcare professionals for chronic conditions is also a contributing factor to the growth of this segment.

Topical Creams:

Topical creams are another critical product type in the Tranilast market, particularly favored in dermatological applications for various skin disorders. These creams are designed for localized treatment, providing direct relief to affected areas, which enhances treatment efficacy while minimizing systemic side effects. The growing incidence of skin-related ailments, including atopic dermatitis and keloids, has significantly increased the demand for topical formulations of Tranilast. Moreover, innovations in transdermal delivery systems have improved the penetration and therapeutic effectiveness of topical creams, making them increasingly popular among dermatologists and patients alike. The segment is anticipated to exhibit steady growth as more patients seek effective topical solutions for their skin-related issues.

Injections:

Injectable forms of Tranilast are primarily utilized for more severe cases where rapid action is necessary. This product type is often indicated for conditions that require immediate therapeutic intervention, such as critical allergic reactions or severe inflammation. The precision of dosage and the ability to achieve quick therapeutic levels in the bloodstream make injections a viable option for healthcare providers when oral or topical forms might not be sufficient. The demand for injectable Tranilast is being fueled by the increasing prevalence of conditions that necessitate swift medical attention. However, the segment's growth is moderated by the preference for less invasive administration methods among patients.

Sprays:

Tranilast sprays are becoming increasingly popular due to their ease of use and quick application, particularly for localized conditions. These sprays are designed to deliver the active ingredient directly onto the affected area, enhancing absorption and providing immediate relief from symptoms. The convenience of sprays caters well to patients who prefer non-invasive treatment options. As more individuals seek effective and user-friendly treatment methods for allergic reactions or localized skin conditions, the spray formulation of Tranilast is expected to see substantial growth. Furthermore, advancements in spray technology that ensure consistent dosing and improved effectiveness are likely to enhance the segment's appeal.

Gels:

Gels form a unique segment within the Tranilast market, offering a lightweight, non-greasy alternative for topical application. These formulations are typically favored for their aesthetic properties and rapid absorption characteristics, making them particularly suitable for patients who are concerned with cosmetic factors. The gel formulation allows for a cooling effect upon application, providing relief from symptoms while enhancing the patient experience. The demand for Tranilast gels is driven by the preference for products that can seamlessly integrate into daily skincare routines, especially among younger demographics seeking effective treatments for skin issues without compromising on comfort or appearance. As awareness regarding the benefits of gel formulations rises, this segment is likely to witness continued growth.

By Application

Dermatology:

Dermatology is the leading application segment for Tranilast, reflecting its established efficacy in treating various skin disorders such as eczema, atopic dermatitis, and hypertrophic scars. The compound's anti-inflammatory properties play a crucial role in managing these conditions by alleviating symptoms and promoting skin healing. Dermatologists often prescribe Tranilast as a first-line treatment due to its favorable safety profile and effectiveness. The increasing awareness regarding skin health and the growing prevalence of dermatological disorders are instrumental in propelling the demand for Tranilast in this segment. Moreover, the introduction of innovative combination therapies incorporating Tranilast is expected to further enhance its application in dermatology, driving market growth.

Ophthalmology:

In ophthalmology, Tranilast finds its application primarily in the treatment of allergic conjunctivitis and other ocular inflammatory conditions. The drug's ability to inhibit mast cell degranulation is particularly beneficial in managing allergic responses affecting the eyes. As allergic conditions continue to rise globally, the demand for effective ophthalmic solutions has surged, positioning Tranilast as a viable treatment option. Additionally, the ongoing research into its potential benefits for other eye-related conditions is likely to expand its usage in ophthalmology further. The segment is expected to experience steady growth as healthcare providers increasingly recognize Tranilast's therapeutic potential in ocular applications.

Rheumatology:

Tranilast is also gaining traction in rheumatology, particularly for its anti-inflammatory effects in various autoimmune and chronic inflammatory diseases. Conditions such as rheumatoid arthritis, where inflammation plays a central role, can benefit from Tranilast's mechanism of action. The growing recognition of the drug's potential in managing these complex disorders has prompted further research and clinical trials to validate its efficacy. As more evidence emerges supporting Tranilast's role in rheumatology, healthcare practitioners may increasingly incorporate it into treatment regimens, contributing to the segment's growth in the coming years. Moreover, the rising prevalence of rheumatic diseases among the aging population is expected to drive the demand for effective treatment options, including Tranilast.

Allergy:

Allergy-related applications represent another significant area for Tranilast, particularly in managing allergic rhinitis and other allergic conditions. The drug's ability to inhibit the release of mediators from mast cells makes it an effective option for alleviating allergic symptoms. The rising prevalence of allergic conditions worldwide is driving the demand for effective therapeutic solutions, making Tranilast a key player in this segment. Recent studies highlighting the benefits of Tranilast in controlling allergy symptoms have further established its significance in the field of allergy management. As consumer awareness of effective allergy treatments increases, the market for Tranilast in allergy applications is poised for growth.

Others:

Tranilast's versatility extends to other applications beyond dermatology, ophthalmology, rheumatology, and allergy, encompassing treatment for conditions such as cardiovascular diseases and certain types of cancer. Ongoing research is uncovering the potential benefits of Tranilast in these areas, leading to an expanded scope of applications. The ability of Tranilast to modulate various biological pathways makes it a candidate for innovative therapeutic approaches. As the body of evidence supporting its efficacy in atypical applications continues to grow, the "Others" segment is likely to gain traction, contributing to the overall expansion of the Tranilast market. The exploration of novel uses of Tranilast, backed by clinical research, will play a pivotal role in shaping the future of this market segment.

By Distribution Channel

Hospitals:

Hospitals remain a primary distribution channel for Tranilast, as they are often the first point of contact for patients seeking treatment for various health conditions. The ability of healthcare professionals to administer Tranilast in a controlled environment ensures effective management of patients with acute conditions. Hospitals not only provide prescription services but also engage in clinical trials and research, further promoting the drug's efficacy and broadening its applications. The increasing patient inflow into hospitals, combined with rising incidences of allergic conditions and skin disorders, is likely to bolster the demand for Tranilast within this channel. Moreover, hospital pharmacies are pivotal in ensuring the availability of Tranilast formulations to patients requiring immediate therapeutic intervention.

Retail Pharmacies:

Retail pharmacies play a significant role in the Tranilast market by providing patients with accessible options for obtaining their prescriptions. As awareness regarding allergic conditions and skin disorders rises, more patients are turning to retail pharmacies for their medication needs. These pharmacies offer a wide range of Tranilast products, including oral tablets and topical formulations, catering to diverse patient preferences. The convenience of retail outlets, along with the personalized service provided by pharmacists, contributes to the growing sales of Tranilast in this segment. Additionally, marketing initiatives and educational campaigns by retail pharmacies can enhance patient awareness, further driving the demand for Tranilast products.

Online Pharmacies:

Online pharmacies have emerged as a rapidly growing distribution channel for Tranilast, reflecting the changing dynamics in consumer behavior and healthcare access. The shift towards online shopping, accelerated by the COVID-19 pandemic, has led to an increase in the number of patients seeking medication over the internet. Online pharmacies offer convenience and often more competitive pricing, making it an attractive choice for consumers. The ease of placing orders and having medications delivered directly to their homes aligns well with the lifestyle of modern consumers. This growing trend is expected to drive the sales of Tranilast through online platforms, as patients become more comfortable with the idea of purchasing medications online. Furthermore, the rising digital literacy and internet penetration in developing regions are likely to bolster the online pharmacy segment.

Specialty Clinics:

Specialty clinics are crucial in the Tranilast distribution chain, particularly for patients with specific health conditions requiring specialized care. These clinics often focus on dermatology, allergy treatments, and rheumatology, making them a key interface for prescribing Tranilast as part of a comprehensive treatment plan. The targeted expertise offered by specialty clinics empowers healthcare professionals to tailor treatment regimens that include Tranilast based on individual patient needs. Additionally, these clinics may engage in clinical trials and research that further validate Tranilast's efficacy in various applications, thus enhancing its reputation and demand. As more patients seek specialized care, the role of specialty clinics in distributing Tranilast is expected to grow significantly.

Others:

This segment encompasses various other distribution channels, including direct sales from manufacturers and alternative healthcare providers. These channels may cater to specific patient demographics or conditions, providing tailored solutions that may not be available through mainstream channels. For instance, some alternative healthcare providers may utilize Tranilast in holistic treatment plans, emphasizing its anti-inflammatory properties. The existence of alternative distribution avenues reflects the diverse landscape of the Tranilast market and the need for flexibility in meeting patient demands. As the market continues to evolve, the "Others" segment may experience growth driven by innovation and an increasing focus on patient-centered care.

By Ingredient Type

Tranilast Alone:

Tranilast alone refers to the formulation that contains only the active ingredient Tranilast without any additional compounds. This formulation is widely used in various applications, particularly dermatology and allergy management. The singular focus on Tranilast allows for clear therapeutic benefits associated with the drug, making it a preferred choice for healthcare providers. The growing demand for pure formulations that prioritize efficacy and minimize potential interactions with other ingredients is driving the shift towards Tranilast alone in prescribing practices. Additionally, the simplicity of this formulation aligns with patient preferences for straightforward treatment options, further enhancing its market presence.

Tranilast Combination:

Tranilast combination formulations incorporate Tranilast alongside other active ingredients to enhance therapeutic effects and broaden the scope of treatment. This segment is gaining traction as healthcare providers increasingly recognize the benefits of combination therapies in managing complex conditions. For instance, combinations that include anti-inflammatory agents or additional antihistamines can provide more comprehensive relief for patients suffering from multi-faceted allergic reactions. The market is witnessing innovations in combination therapies that maximize the benefits of Tranilast while minimizing side effects. Ongoing research into the synergistic effects of Tranilast with other compounds is expected to drive growth in this segment, as healthcare practitioners seek out more effective treatment options for their patients.

By Region

The North American Tranilast market is characterized by robust growth, propelled by high healthcare expenditure, advanced medical facilities, and increasing awareness regarding allergic conditions. The region accounted for approximately 35% of the global market share in 2023, with a projected CAGR of around 5.8% during the forecast period. The presence of well-established pharmaceutical companies, coupled with rigorous research and development initiatives, is fostering innovation and expanding the range of Tranilast applications. Furthermore, the growing prevalence of dermatological and allergic conditions in the United States and Canada is driving demand for effective therapeutic solutions, contributing to the region's dominant market position.

In Europe, the Tranilast market is expected to witness steady growth, primarily due to the increasing incidences of allergic diseases and skin disorders among the population. With a market share of approximately 30% in 2023, Europe is anticipated to experience a CAGR of around 6.1% over the forecast period. The European region benefits from strong regulatory frameworks and extensive healthcare infrastructure, which facilitate the availability of Tranilast products to patients. Additionally, the rising emphasis on patient-centric care and personalized treatment approaches is likely to boost the adoption of Tranilast in various applications across Europe. Emerging markets in Eastern Europe are also expected to contribute to the overall market growth as healthcare access improves.

Opportunities

The Tranilast market is poised to capitalize on several opportunities in the coming years. One significant opportunity lies in the growing demand for effective treatments for chronic diseases, such as atopic dermatitis and allergic rhinitis, where Tranilast has been recognized for its therapeutic benefits. The increasing awareness among healthcare professionals and patients regarding the potential applications of Tranilast in managing various health conditions can drive clinical adoption. Furthermore, the expansion of online pharmacies presents a lucrative opportunity for manufacturers and distributors to reach a wider audience, enhancing accessibility to Tranilast products. As more patients turn to online platforms for their medication needs, businesses can leverage this trend to boost sales and brand recognition.

Another opportunity exists in the realm of research and development, where ongoing clinical trials and studies may uncover new therapeutic uses for Tranilast beyond its traditional applications. As researchers explore its potential role in treating conditions like cardiovascular diseases and certain cancers, this could open new commercial avenues for Tranilast. The collaboration between pharmaceutical companies and research institutions can lead to innovative formulations and combination therapies, further enhancing Tranilast's market appeal. Additionally, the increasing focus on personalized medicine provides an opportunity to develop tailored Tranilast solutions that cater to specific patient demographics, thereby improving treatment outcomes and fostering long-term loyalty among healthcare providers and patients.

Threats

The Tranilast market faces several threats that could impact its growth trajectory. One of the primary threats is the emergence of generic alternatives, which may offer similar therapeutic benefits at lower prices. As patent protections expire, the influx of generics can lead to increased price competition, potentially eroding market share for branded Tranilast products. This price sensitivity among consumers and healthcare providers could, in turn, pressure manufacturers to reduce prices, impacting profit margins. Furthermore, aggressive marketing strategies by generic pharmaceutical companies may shift the focus away from branded Tranilast, creating challenges for retention of market position.

Additionally, regulatory changes and stringent approval processes for new drug formulations can pose significant threats to the Tranilast market. Variations in regulatory requirements across different regions could slow down the introduction of new products and limit market expansion opportunities. Moreover, the increasing scrutiny on pharmaceutical pricing and the push for cost-effective treatment options could lead to government interventions that impact Tranilast's pricing strategies. These factors collectively contribute to an uncertain market landscape, necessitating vigilance and adaptability from industry players to navigate potential disruptions successfully.

Competitor Outlook

• Roche Holding AG
• Mitsubishi Tanabe Pharma Corporation
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Ltd.
• Sun Pharmaceutical Industries Ltd.
• Fujifilm Corporation
• Takeda Pharmaceutical Company Limited
• Hikma Pharmaceuticals PLC
• Hoffmann-La Roche Ltd.
• Almirall, S.A.
• MSD (Merck Sharp & Dohme) Corp.
• Novartis AG
• Pfizer Inc.
• Boehringer Ingelheim GmbH
• AbbVie Inc.

The competitive landscape of the Tranilast market is characterized by the presence of several established pharmaceutical companies as well as emerging players actively engaged in developing and distributing Tranilast formulations. Leading companies like Roche Holding AG and Mitsubishi Tanabe Pharma Corporation are at the forefront, leveraging their extensive research capabilities, robust distribution networks, and established brand recognition to capture a significant market share. These industry giants have invested heavily in research and development, enabling them to explore innovative applications and formulations of Tranilast, thereby enhancing their competitive edge. Moreover, collaborations and partnerships with healthcare institutions and research organizations have fostered an environment conducive to clinical trials and product validation, further solidifying their market position.

Emerging players such as Glenmark Pharmaceuticals and Sun Pharmaceutical Industries are also gaining traction in the Tranilast market. These companies focus on niche segments and often adopt aggressive pricing strategies to attract price-sensitive consumers. By developing cost-effective formulations and exploring new geographic markets, these companies are carving out their space in the market. Additionally, as the demand for effective treatments for chronic conditions rises, these emerging players are well-positioned to capitalize on the growing market opportunities. Their agility and adaptability in responding to market trends and customer needs provide them with a competitive advantage in the evolving landscape.

Moreover, the trend towards consolidation within the pharmaceutical industry is reshaping the competitive dynamics of the Tranilast market. Mergers and acquisitions among key players may lead to the development of comprehensive portfolios that include Tranilast alongside complementary therapeutic options. This strategy can enhance the value proposition for healthcare providers and patients, providing a one-stop solution for specific health conditions. As the industry evolves, companies will need to remain vigilant in monitoring competitor activities and market trends to maintain their competitive advantage and capitalize on emerging opportunities effectively.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 AbbVie Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Almirall, S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Roche Holding AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Fujifilm Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Hoffmann-La Roche Ltd.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Boehringer Ingelheim GmbH
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Hikma Pharmaceuticals PLC
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Glenmark Pharmaceuticals Ltd.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 MSD (Merck Sharp & Dohme) Corp.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Sun Pharmaceutical Industries Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Teva Pharmaceutical Industries Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Mitsubishi Tanabe Pharma Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Tranilast Market, By Application
    • 6.1.1 Dermatology
    • 6.1.2 Ophthalmology
    • 6.1.3 Rheumatology
    • 6.1.4 Allergy
    • 6.1.5 Others
  • 6.2 Tranilast Market, By Product Type
    • 6.2.1 Oral Tablets
    • 6.2.2 Topical Creams
    • 6.2.3 Injections
    • 6.2.4 Sprays
    • 6.2.5 Gels
  • 6.3 Tranilast Market, By Ingredient Type
    • 6.3.1 Tranilast Alone
    • 6.3.2 Tranilast Combination
  • 6.4 Tranilast Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Specialty Clinics
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Tranilast Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Tranilast market is categorized based on

By Product Type

• Oral Tablets
• Topical Creams
• Injections
• Sprays
• Gels

By Application

• Dermatology
• Ophthalmology
• Rheumatology
• Allergy
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• Others

By Ingredient Type

• Tranilast Alone
• Tranilast Combination

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Holding AG
• Mitsubishi Tanabe Pharma Corporation
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Ltd.
• Sun Pharmaceutical Industries Ltd.
• Fujifilm Corporation
• Takeda Pharmaceutical Company Limited
• Hikma Pharmaceuticals PLC
• Hoffmann-La Roche Ltd.
• Almirall, S.A.
• MSD (Merck Sharp & Dohme) Corp.
• Novartis AG
• Pfizer Inc.
• Boehringer Ingelheim GmbH
• AbbVie Inc.